On Tuesday, Olema Pharmaceuticals Inc (NASDAQ: OLMA) opened higher 18.50% from the last session, before settling in for the closing price of $5.46. Price fluctuations for OLMA have ranged from $2.86 to $13.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -83.00% over the last five years. Company’s average yearly earnings per share was noted 14.05% at the time writing. With a float of $52.83 million, this company’s outstanding shares have now reached $68.63 million.
Olema Pharmaceuticals Inc (OLMA) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Olema Pharmaceuticals Inc is 23.02%, while institutional ownership is 85.69%. The most recent insider transaction that took place on Jan 08 ’25, was worth 1,727,370. In this transaction 10% Owner of this company bought 300,000 shares at a rate of $5.76, taking the stock ownership to the 7,800,000 shares. Before that another transaction happened on Dec 17 ’24, when Company’s Director sold 700,761 for $6.75, making the entire transaction worth $4,730,137. This insider now owns 0 shares in total.
Olema Pharmaceuticals Inc (OLMA) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.6 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.57) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.56% during the next five years compared to -83.00% drop over the previous five years of trading.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) Trading Performance Indicators
Check out the current performance indicators for Olema Pharmaceuticals Inc (OLMA). In the past quarter, the stock posted a quick ratio of 15.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -2.14 in one year’s time.
Technical Analysis of Olema Pharmaceuticals Inc (OLMA)
Analysing the last 5-days average volume posted by the [Olema Pharmaceuticals Inc, OLMA], we can find that recorded value of 0.49 million was lower than the volume posted last year of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 45.13%.
During the past 100 days, Olema Pharmaceuticals Inc’s (OLMA) raw stochastic average was set at 99.15%, which indicates a significant increase from 97.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.33 in the past 14 days, which was lower than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.98, while its 200-day Moving Average is $5.41. Now, the first resistance to watch is $6.86. This is followed by the second major resistance level at $7.25. The third major resistance level sits at $8.00. If the price goes on to break the first support level at $5.72, it is likely to go to the next support level at $4.97. Should the price break the second support level, the third support level stands at $4.58.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) Key Stats
There are currently 68,634K shares outstanding in the company with a market cap of 444.06 million. Presently, the company’s annual sales total 0 K according to its annual income of -129,470 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -43,780 K.
